GLP1R and inflammatory bowel disease: While these changes do not seem to be particularly pushing towards anti- or pro-inflammatory bacteria, GLP-1 agonists were shown to have an overall anti-inflammatory response and the implications to treat a variety of diseases other than T2DM including inflammatory bowel disease (IBD) and neurodegenerative disease are being widely studied [258].